Will IT pharma really make the most of rupee slide to benefit investors

INSUBCONTINENT EXCLUSIVE:
D K AggarwalThe slide in the rupee, in line with emerging market currencies, is increasingly being recognised as a concern for the Indian
economy
Also, emerging market companies and governments combating rising cost of borrowing in dollars face increasing pressure as $249 billion
needs to be repaid or refinanced through next year
There is a sense of cautiousness among investors because rising rates mean they need to pay more for unprecedented amount of borrowing,
which could push balancesheets of emerging companies towards a tipping point. If data are to be believed, the rupee has depreciated between
March-end and mid-May on the back of rise in US treasury yields
Besides, the surge in prices of industrial metals and oil, sanctions against Russian companies contributing to the former, hardening demand
and falling inventories dragged the rupee much lower
Apart from above factors, persistent outflow of foreign funds from the Indian stock as well as bond markets has also impacted rupee
performance
The rupee has weakened by 6.44 percent so far in 2018
There is cautiousness among investors that rupee depreciation, if the trend continues, could compel the RBI to increase policy rates
higher. The sharp slide in the rupee may not only impact fiscal mathematics, but severely affect the cost of borrowings for the corporate
sector
Undoubtedly, the drop has been discomforting investors as a weaker rupee could spell trouble for a number of sectors that have a higher
amount of dollar-denominated debt on their books
To name a few are oil marketing companies, power and telecom players, automobile firms and capital goods companies
On the flip side, with a depreciating rupee, the value of exports would naturally increase
Hence, it would be a boon for the export-oriented sectors such as IT and pharma with a large exposure to the US
IT firms such as Infosys, TCS, HCL Technologies and pharma players Sun Pharma, Lupin, Cadila , Ajanta Pharma and Aurobindo Pharma are a case
in point
Investors may invest in these stocks and can take benefit of the rupee depreciating scenario, but they need to check if the company they
intend to invest in have healthy business prospects and margins.